Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Response to chemotherapy in relapsed low-grade serous ovarian carcinoma: Royal Marsden series of 46 patients

Date

08 Oct 2016

Session

Poster Display

Presenters

Jennifer McLachlan

Citation

Annals of Oncology (2016) 27 (6): 296-312. 10.1093/annonc/mdw374

Authors

J.M. McLachlan1, N. Tunariu1, J.P. Lima2, A. George1, M. Gore2, S. Kaye2, S. Banerjee2

Author affiliations

  • 1 Gynaecology Unit, Royal Marsden Hospital NHS Foundation Trust, SW36JJ - London/GB
  • 2 Gynaecology Unit, Royal Marsden Hospital NHS Foundation Trust, London/GB
More

Resources

Abstract 2552

Background

Low-grade serous carcinoma (LGSC) of the ovary/peritoneum is characterised by relative resistance to chemotherapy, however there are no reported prospective studies of chemotherapy specifically in this rare subtype. The purpose of this study was to evaluate the response to chemotherapy in patients with relapsed LGSC treated at a single cancer centre.

Methods

A search of a database of patients with histologically confirmed LGSC treated at the Royal Marsden Hospital between 1990-2015 was performed. Patients treated with chemotherapy in the relapsed setting with radiologically evaluable disease were included in the study. Histological confirmation of LGSC was performed by a gynae-oncology pathologist. Response was determined by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 and confirmed by a radiologist. The primary endpoint was objective response rate (ORR). Secondary endpoints included overall survival (OS) and progression-free survival (PFS).

Results

Forty-six patients with relapsed LGSC with evaluable disease, treated with 77 separate chemotherapy regimens were included in the study. The median age at diagnosis was 49 years (range 22-80 years). There were 8 partial responses with an ORR of 10.4%. The median duration of response was 11.2 months. Stable disease was achieved in 58 of 77 (75.3%) treatment regimens. The stable disease rate at 6 months was 43%. The ORR for the platinum-sensitive cohort was 11.3% and 8.3% for the platinum-resistant cohort. The median OS was 62 months and median PFS was 8.2 months.

Conclusions

Relapsed LGSC is relatively resistant to chemotherapy in comparison to the most common subtype, high-grade serous carcinoma. In our series, the response rate to chemotherapy (10.4%) for recurrent LGSC is higher than previously published retrospective series (3.7%). Chemotherapy should be considered an option for recurrent LGSC. There is an urgent need for better therapies and identification of LGSC patients who are more likely to respond to chemotherapy. Patients should be enrolled into clinical trials of novel targeted agents.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

Royal Marsden NHS Foundation Trust

Disclosure

S. Banerjee: Chief investigator for the MILO Study in the United Kingdom. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings